Blogs

DNA Electronics appoints Nick McCooke as Chief Business Officer

London, UK, 10th June 2014 – DNA Electronics Ltd (DNAe), a provider of point-of-care genomic diagnostics solutions for medical and healthcare applications, today announces the appointment of Nick McCooke as Chief Business Officer as it continues to build its management team.

Mr McCooke brings 30 years of senior management experience in Healthcare businesses. As CEO of Solexa, from its spin-out from the University of Cambridge in 2000 to its NASDAQ listing in 2005, he led the development of the world’s leading Next Generation DNA Sequencing (NGS) technology, which is the basis of Illumina’s current product line.

Mr McCooke comments: “I’m thrilled to be joining DNAe at this exciting point in the company’s evolution. I was proud to be part of the NGS revolution ten years ago and I believe that bringing the technology to clinicians at the point of need is the next revolution.”

Learn How to Streamline the Regulatory Approval Process and Accelerate Time to Market at the Medical Device Manufacturer’s Assoc

Glendale, CA, USA, 8th May 2014 – Across Systems, a leading software platform for all corporate language resources and translation processes, announced today that the Company will be attending the 2014 Medical Device Manufacturer’s Association Annual Conference to meet with interested parties about ways to streamline the regulatory approval process. The conference will take place in Washington DC May 14 – 16, 2014.

The Medical Device Manufacturers Association (MDMA) is a national trade association based in Washington, DC providing educational and advocacy assistance to innovative and entrepreneurial medical technology companies. This year's meeting will provide the latest on regulatory, reimbursement, compliance and international trends, as well as share powerful stories of how med tech is improving patient care.

DNA Electronics Appoints Dr Steve Allen As Chief Operating Officer; Expands Product Development Team

London, UK, 8th May 2014. – DNA Electronics Ltd, a provider of point-of-care genomic diagnostics solutions for medical and healthcare applications, today announces the appointment of Dr Steve Allen as Chief Operating Officer, along with the doubling of its development team from 30 to 60 scientists and engineers. The appointment of Dr Allen and the expansion of DNA Electronics’ product development capabilities follows the recent investment in the company by the Genting Group.

DNA Electronics Secures Funding From Genting Berhad To Develop Genalysis® Point-of-Care Genomic Diagnostics Product Line

London, United Kingdom, 28th April 2014 – DNA Electronics Ltd (DNAe), a developer of semiconductor solutions for real-time DNA and RNA detection, today announces that it had successfully secured the necessary funding for DNAe to develop the Genalysis® point-of-care genomic diagnostic product line. The majority of the funding had been provided by its principal shareholder, Edith Grove Limited (a wholly owned subsidiary of Genting Berhad), with the company’s founders also making further investment. DNAe will utilise the funding to transform the company from an R&D and licensing business to a full-fledged product company, offering point-of-care solutions for time-critical medical applications.

Advancing the frontiers of cancer research

Abingdon, UK, 23rd April 2014 – Oxford Optronix, the leading provider of advanced research instrumentation for the clinical medicine and life science industries, today releases a new whitepaper outlining the potential of automated colony counting and imaging systems for making major advances in cancer research.

“Advancing the frontiers of cancer research: automated colony counting for cancer biologists” is freely available for download now from the Oxford Optronix website: http://www.optronix1.com/white-paper/

In the wake of recent landmark discoveries into the molecular and biological changes underlying cancer development, laboratories are attempting to manage “industrial scale” research alongside increasingly restrained budgets from public and private funding bodies. The emergence of three dimensional arrays have only added to these pressures, as manually colony counting these complex in vitro culture systems is proving too labour intensive for laboratories to handle.

Global regulatory affairs specialist ELC Group appoints Localization Business Development Manager for new US Office

Cambridge, UK, 14th April 2014 – ELC Group, one of the fastest-growing providers of regulatory affairs, today announces the appointment of Suzanne Morris as Localization Business Development Manager for North America, heading up its newly opened operational office in Philadelphia, PA.

Responding to the rapid growth of its North America client base, ELC Group’s new US office will focus on providing language translation and localization services for an array of industry sectors, ranging from Life Sciences to Consumer Electronics and Military. The new US headquarters establishes a key regional base from which ELC Group plans to aggressively accelerate its language translation and localization services sales in North and South America, led by experienced business development executive Suzanne Morris.

Pages

Subscribe to RSS - blogs